FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046493188> ?p ?o ?g. }

• W2046493188 endingPage "233" @default.
• W2046493188 startingPage "226" @default.
• W2046493188 abstract "The objectives of this trial were to define the toxicity profile, dose, pharmacokinetics, and pharmacodynamics of the farnesyl transferase (FTase) inhibitor, tipifarnib, in children and adolescents with hematological malignancies.Tipifarnib was administered twice daily for 21 days, repeated every 28 days starting at a dose of 300 mg/m(2) /dose. Pharmacokinetic sampling was performed for 36 hr after the first dose and leukemic blasts were collected pre-treatment and at steady state for determination of FTase activity.Of 29 patients enrolled, 18 were fully evaluable for toxicity, and 23 for response; 26 had pharmacokinetic and pharmacodynamic sampling. The recommended dose is 300 mg/m(2) /dose and toxicities included skin rash, mucositis, nausea, vomiting, and diarrhea. Neurotoxicity, which was dose-limiting in adults at doses exceeding 600 mg/dose, was infrequent and mild. The plasma pharmacokinetics of tipifarnib were highly variable but comparable to adults with acute leukemia and children with solid tumors. The median apparent clearance of tipifarnib was 630 ml/min/m(2) and the median half-life was 4.7 hr. At steady state on 300 mg/m(2) /dose, FTase activity was inhibited by 82% in leukemic blasts. No objective responses were observed.Oral tipifarnib is well tolerated in children with leukemia on a twice daily for 2 days schedule at 300 mg/m(2) /dose." @default.
• W2046493188 created "2016-06-24" @default.
• W2046493188 creator A5001384011 @default.
• W2046493188 creator A5009042526 @default.
• W2046493188 creator A5012188951 @default.
• W2046493188 creator A5027165899 @default.
• W2046493188 creator A5027468886 @default.
• W2046493188 creator A5050738935 @default.
• W2046493188 creator A5054358161 @default.
• W2046493188 creator A5066484657 @default.
• W2046493188 creator A5071679104 @default.
• W2046493188 creator A5082967648 @default.
• W2046493188 creator A5090559168 @default.
• W2046493188 date "2010-09-21" @default.
• W2046493188 modified "2023-10-10" @default.
• W2046493188 title "Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group" @default.
• W2046493188 cites W126176001 @default.
• W2046493188 cites W1974740049 @default.
• W2046493188 cites W2024196844 @default.
• W2046493188 cites W2025754007 @default.
• W2046493188 cites W2052954337 @default.
• W2046493188 cites W2057228368 @default.
• W2046493188 cites W2077777928 @default.
• W2046493188 cites W2079412873 @default.
• W2046493188 cites W2102901804 @default.
• W2046493188 cites W2125244026 @default.
• W2046493188 cites W2133764101 @default.
• W2046493188 cites W2137343757 @default.
• W2046493188 cites W2142436421 @default.
• W2046493188 cites W2147126709 @default.
• W2046493188 cites W2172062373 @default.
• W2046493188 cites W2316903752 @default.
• W2046493188 cites W2324953630 @default.
• W2046493188 cites W2979946515 @default.
• W2046493188 doi "https://doi.org/10.1002/pbc.22775" @default.
• W2046493188 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3271115" @default.
• W2046493188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20860038" @default.
• W2046493188 hasPublicationYear "2010" @default.
• W2046493188 type Work @default.
• W2046493188 sameAs 2046493188 @default.
• W2046493188 citedByCount "23" @default.
• W2046493188 countsByYear W20464931882012 @default.
• W2046493188 countsByYear W20464931882013 @default.
• W2046493188 countsByYear W20464931882014 @default.
• W2046493188 countsByYear W20464931882015 @default.
• W2046493188 countsByYear W20464931882016 @default.
• W2046493188 countsByYear W20464931882017 @default.
• W2046493188 countsByYear W20464931882018 @default.
• W2046493188 countsByYear W20464931882020 @default.
• W2046493188 countsByYear W20464931882021 @default.
• W2046493188 countsByYear W20464931882022 @default.
• W2046493188 crossrefType "journal-article" @default.
• W2046493188 hasAuthorship W2046493188A5001384011 @default.
• W2046493188 hasAuthorship W2046493188A5009042526 @default.
• W2046493188 hasAuthorship W2046493188A5012188951 @default.
• W2046493188 hasAuthorship W2046493188A5027165899 @default.
• W2046493188 hasAuthorship W2046493188A5027468886 @default.
• W2046493188 hasAuthorship W2046493188A5050738935 @default.
• W2046493188 hasAuthorship W2046493188A5054358161 @default.
• W2046493188 hasAuthorship W2046493188A5066484657 @default.
• W2046493188 hasAuthorship W2046493188A5071679104 @default.
• W2046493188 hasAuthorship W2046493188A5082967648 @default.
• W2046493188 hasAuthorship W2046493188A5090559168 @default.
• W2046493188 hasBestOaLocation W20464931882 @default.
• W2046493188 hasConcept C111113717 @default.
• W2046493188 hasConcept C112705442 @default.
• W2046493188 hasConcept C121332964 @default.
• W2046493188 hasConcept C126322002 @default.
• W2046493188 hasConcept C142424586 @default.
• W2046493188 hasConcept C2778461978 @default.
• W2046493188 hasConcept C2778496288 @default.
• W2046493188 hasConcept C2780580376 @default.
• W2046493188 hasConcept C2780852908 @default.
• W2046493188 hasConcept C29730261 @default.
• W2046493188 hasConcept C71924100 @default.
• W2046493188 hasConcept C87355193 @default.
• W2046493188 hasConcept C90924648 @default.
• W2046493188 hasConcept C98274493 @default.
• W2046493188 hasConceptScore W2046493188C111113717 @default.
• W2046493188 hasConceptScore W2046493188C112705442 @default.
• W2046493188 hasConceptScore W2046493188C121332964 @default.
• W2046493188 hasConceptScore W2046493188C126322002 @default.
• W2046493188 hasConceptScore W2046493188C142424586 @default.
• W2046493188 hasConceptScore W2046493188C2778461978 @default.
• W2046493188 hasConceptScore W2046493188C2778496288 @default.
• W2046493188 hasConceptScore W2046493188C2780580376 @default.
• W2046493188 hasConceptScore W2046493188C2780852908 @default.
• W2046493188 hasConceptScore W2046493188C29730261 @default.
• W2046493188 hasConceptScore W2046493188C71924100 @default.
• W2046493188 hasConceptScore W2046493188C87355193 @default.
• W2046493188 hasConceptScore W2046493188C90924648 @default.
• W2046493188 hasConceptScore W2046493188C98274493 @default.
• W2046493188 hasIssue "2" @default.
• W2046493188 hasLocation W20464931881 @default.
• W2046493188 hasLocation W20464931882 @default.
• W2046493188 hasLocation W20464931883 @default.
• W2046493188 hasLocation W20464931884 @default.
• W2046493188 hasOpenAccess W2046493188 @default.

• next